Evidence map›Paper›PMID 23577227›Full record

ReviewOxidative medicine and cellular longevity2013

Diversity of mitochondrial pathology in a mouse model of axonal degeneration in synucleinopathies.

Akio Sekigawa, Yoshiki Takamatsu, Kazunari Sekiyama, Takato Takenouchi, Shuei Sugama, Masaaki Waragai, Masayo Fujita, Makoto Hashimoto

Open access · hybridAbstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Akio SekigawaTokyo Metropolitan Institute of Medical Sciences, Tokyo, Japan.
Yoshiki Takamatsu
Kazunari Sekiyama
Takato Takenouchi
Shuei Sugama
Masaaki Waragai
Masayo Fujita
Makoto Hashimoto
Tokyo Metropolitan Institute of Medical Science · JPInstitute of Agrobiological Sciences · JPNippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is mounting evidence for a role of mitochondrial dysfunction in the pathogenesis of α -synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB). In particular, recent studies have demonstrated that failure of mitochondrial quality control caused by loss of function of the PTEN-induced kinase 1 (PINK1, PARK6) Parkin (PARK2) pathway may be causative in some familial PD. In sporadic PD, α -synuclein aggregation may interfere with mitochondrial function, and this might be further exacerbated by leucine-rich repeat kinase 2 (LRRK2). The majority of these findings have been obtained in Drosophila and cell cultures, whereas the objective of this paper is to discuss our recent results on the axonal pathology of brains derived from transgenic mice expressing α -synuclein or DLB-linked P123H β -synuclein. In line with the current view of the pathogenesis of sporadic PD, mitochondria abnormally accumulated in α -synuclein/LRRK2-immunopositive axonal swellings in mice expressing α -synuclein. Curiously, neither mitochondria nor LRRK2 was present in the swellings of mice expressing P123H β -synuclein, suggesting that α - and β -synuclein might play differential roles in the mitochondrial pathology of α -synucleinopathies.

Indexed as

AnimalsAxonsDementiaDisease Models, AnimalLewy Body DiseaseMitochondriaParkinson DiseaseProtein KinasesPTEN-Induced Putative KinaseSynucleinsProtein KinasesPTEN-Induced Putative KinaseSynucleins

Identifiers

PMID23577227
PMCPMC3612494
OpenAlexW2061400050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.